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The population of Pakistan has been reported to have the highest rate of breast cancer of any Asian population
(excluding Jews in Israel) and one of the highest rates of ovarian cancer worldwide. To explore the contribution
that genetic factors make to these high rates, we have conducted a case-control study of 341 case subjects with
breast cancer, 120 case subjects with ovarian cancer, and 200 female control subjects from two major cities of
Pakistan (Karachi and Lahore). The prevalence of BRCA1 or BRCA2 mutations among case subjects with breast
cancer was 6.7% (95% confidence interval [CI] 4.1%–9.4%), and that among case subjects with ovarian cancer
was 15.8% (95% CI 9.2%–22.4%). Mutations of the BRCA1 gene accounted for 84% of the mutations among
case subjects with ovarian cancer and 65% of mutations among case subjects with breast cancer. The majority of
detected mutations are unique to Pakistan. Five BRCA1 mutations (2080insA, 3889delAG, 4184del4, 4284delAG,
and IVS14-1ArG) and one BRCA2 mutation (3337CrT) were found in multiple case subjects and represent
candidate founder mutations. The penetrance of deleterious mutations in BRCA1 and BRCA2 is comparable to
that of Western populations. The cumulative risk of cancer to age 85 years in female first-degree relatives of BRCA1-
mutation–positive case subjects was 48% and was 37% for first-degree relatives of the BRCA2-mutation–positive
case subjects. A higher proportion of case subjects with breast cancer than of control subjects were the progeny
of first-cousin marriages (odds ratio [OR] 2.1; 95% CI 1.4–3.3; ). The effects of consanguinity werePp .001
significant for case subjects with early-onset breast cancer (age !40 years) ( ; 95% CI 1.5–4.9;ORp 2.7 Pp
) and case subjects with ovarian cancer ( ; 95% CI 1.4–4.2; ). These results suggest that.0008 ORp 2.4 Pp .002
recessively inherited genes may contribute to breast and ovarian cancer risk in Pakistan.
Introduction
Carcinoma of the breast is the most common cancer
among women in Pakistan, with incidence rates that re-
semble those reported in the West (Malik et al. 1992;
Bhurgri et al. 2000). Affected women are typically young
and often present with advanced disease (Usmani et al.
1996; Ahmed et al. 1997). The age-standardized (world)
rate (ASR) of breast cancer in Karachi, Pakistan, is 51.7
per 100,000 per year and is the highest ASR reported for
any Asian population, excluding Israel (Parkin et al. 1997;
Bhurgri et al. 2000). All other Asian registries report
breast cancer rates !40 per 100,000 per year, except for
Manila in the Philippines (47.7 per 100,000 per year)
(Parkin et al. 1997). The breast cancer rates reported in
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provinces of neighboring India—ranging from 8.7 per
100,000 per year, in Barshi, Paranda, and Bhum, to 28.2
per 100,000 per year, in Bombay—are considerably lower
than those in Pakistan (Parkin et al. 1997).
In North America, age-specific rates of breast cancer
double approximately every 10 years until menopause,
after which the rates continue to increase slowly. This
pattern of rapid premenopausal growth is also seen in
Pakistan, but breast cancer risk plateaus after age 45
years. This difference in the slope of the age-specific–
incidence curves in Eastern and Western populations
indicates that premenopausal breast cancer is relatively
more common among Asian populations. Studies on the
Pakistani population may further our understanding of
the etiology of breast cancer in young Asian women.
Carcinoma of the ovary is the most common cancer
of gynecologic origin in Pakistan (Bhurgri et al. 2000).
The ASR of ovarian cancer in Karachi, Pakistan (10.2
per 100,000 per year), is comparable to that of Ontario,
Canada (10.7 per 100,000 per year) (Parkin et al. 1997;
Bhurgri et al. 2000). In contrast, adjusted ovarian can-
cer rates in India range from 1.2 per 100,000 per year,
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in Barshi, Paranda, and Bhum, to 7.2 per 100,000 per
year, in Bombay.
The reasons for the relatively high rates of cancers of
the breast and the ovary in Pakistan are not known.
Lifestyle and reproductive factors may influence the in-
cidence of breast and ovarian cancer, but the specific
factors have not been identified. It is also possible that
genetic factors, such as mutations in the breast and ovar-
ian cancer–susceptibility genes BRCA1 (MIM 113705)
and BRCA2 (MIM 600185), may contribute to a sig-
nificant proportion of breast and ovarian cancer sus-
ceptibility. Pakistan has one of the highest rates of con-
sanguinity in the world (Hashmi 1997). The overall
frequency of consanguineous marriages is 60%–76% in
Pakistan, and that frequency is 75% among Pakistanis
living in the United Kingdom (Darr and Modell 1988;
Hashmi 1997; Hussain and Bittles 1998). Inbreeding is
known to increase the risk of diseases caused by ho-
mozygosity of deleterious recessive genes. Parental con-
sanguinity has been implicated in 60% of mortality and
severe morbidity in Pakistani children born in Britain,
and autosomal recessive disorders affect 3.7% of all
Pakistani children (Powell et al. 1995). An excess of
childhood cancers was also reported among children of
consanguineous marriages in Britain (Powell et al.
1995). There is little information on the possible role
that recessive genes play in adult cancer. One study from
Pakistan has described an association between consan-
guinity and the risk of breast cancer (Shami et al. 1991).
Study of the Pakistani population offers the potential
to explore the contribution that consanguinity makes
to breast and ovarian cancer rates.
To date, no investigations have been undertaken that
explore the contribution, to breast and ovarian cancer
susceptibility in Pakistan, of dominant and recessive ge-
netic factors. We conducted a hospital-based case-con-
trol study of 341 case subjects with breast cancer, 120
case subjects with ovarian cancer, and 200 unaffected
female control subjects from two major cities of Paki-
stan (Karachi and Lahore).
Subjects and Methods
Subjects and Study Design
Women who have had invasive breast cancer or epi-
thelial ovarian cancer diagnosed were ascertained at the
National Cancer Institute (NCIK), in Karachi, from Au-
gust 1998 to August 2000, and at the Jinnah Hospital
(JHL), in Lahore, from August 1999 to August 2001.
Case and control subjects were interviewed during hos-
pital visits at in- and outpatient clinics. Women were
asked for their pregnancy history; for information on
cancer treatment, previous surgeries, selected lifestyle
factors, and parental marital relationships (i.e., consan-
guinity); and for detailed information on family history
of cancer. Recruitment occurred during a 1-year period
at each center. All case subjects with cancer were con-
firmed histologically. JHL is a government-sponsored
hospital, whereas NCIK is a private hospital that offers
only oncology services. The case subjects were women
with breast or ovarian cancer who were treated, during
the study period, by the chief medical oncologist at each
of the two hospitals (I.A.M. and Z.A.). Prevalent and
incident cases were included. In prevalent cases, diag-
nosis was made 11 year before the date of interview.
Case subjects were unselected for age or family history.
Questionnaire data and blood specimens were col-
lected from 341 case subjects with invasive breast cancer
and 120 case subjects with invasive epithelial ovarian
cancer. JHL contributed 102 case subjects with breast
cancer and 54 case subjects with ovarian cancer, and
NCIK contributed 239 case subjects with breast cancer
and 66 case subjects with ovarian cancer. The majority
of case subjects represented incident cases (i.e., were in-
terviewed within 1 year of diagnosis); case subjects who
represented prevalent cases comprised 11% of ovarian
cancer cases and 25% of breast cancer cases.
For the evaluation of the potential importance of con-
sanguinity as a risk factor for breast cancer, a control
group was required. This study included hospital-based
control subjects who were identified at various in- and
outpatient clinics in local noncancer hospitals (Karachi)
or in the same hospital (Lahore). The control subjects
were 200 women with no previous diagnosis of cancer.
The majority (89%) of control subjects were ascertained
at various in- and outpatient services from local hospitals
in Karachi; 22 (11%) control subjects were from out-
patient clinics at JHL. The control group was composed
of women attending in- and outpatient services for gen-
eral medical (20%), antenatal (20%), infectious disease
(15.5%), gynecologic (noncancer) (15%), maternity
(8%), and surgical (5%) departments of the hospitals.
Eleven (5.5%) spouses of male patients with cancer were
also included as control subjects. Because consanguinity
rates are likely to vary by year of birth, by geographic
region, by socioeconomic status, and by ethnic group,
data on these variables were collected from case and
control subjects. Annual income was considered as a
surrogate for socioeconomic status.
BRCA1 and BRCA2 Analysis
Human genomic DNA was isolated from 20 mL of
peripheral blood. Blood specimens were sent to the mo-
lecular laboratory of the Sunnybrook & Women’s Col-
lege Health Sciences Centre, in Toronto, Canada. A va-
riety of methods were employed to detect the presence
of a BRCA1 or BRCA2 mutation. Exon 11 of BRCA1
and exons 10 and 11 of BRCA2 were screened by pro-
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Table 1
Frequency of Mutations in Cases of Breast and Ovarian Cancer
by Age at Diagnosis
PATIENT GROUPS BASED
ON TYPE OF CANCER
AND AGE (IN YEARS)
TOTAL NO.
OF PATIENTS
NO. (%) POSITIVE
FOR MUTATION IN
BRCA1 BRCA2
Either BRCA1
or BRCA2
Breast cancer:
20–29 23 1 (4.3) 0 (.0) 1 (4.3)
30–39 136 11 (8.1) 3 (2.2) 14 (10.3)
40–49 137 3 (2.2) 3 (2.2) 6 (4.4)
50–59 29 0 (.0) 0 (.0) 0 (.0)
60 16 0 (.0) 2 (1.3) 2 (1.3)
All ages 341 15 (4.4) 8 (2.3) 23 (6.7)
Ovarian cancera:
20–29 15 0 (.0) 0 (.0) 0 (.0)
30–39 18 2 (11.1) 0 (.0) 2 (11.1)
40–49 41 6 (14.6) 2 (4.9) 8 (19.5)
50–59 32 5 (15.6) 1 (3.1) 6 (18.8)
60 14 3 (21.4) 0 (.0) 3 (21.4)
All ages 120 16 (13.3) 3 (2.5) 19 (15.8)
a Included here, four cases with separate primary cancers of the breast and ovary.
tein-truncation testing (PTT), in all case subjects (see the
Genome Database Web site). All mutant bands detected
by PTT were confirmed by direct sequencing.
Nine case subjects who had two or more relatives with
either breast cancer diagnosed at age !50 years or ovar-
ian cancer and in whom no mutation was found were
selected for complete screening by the direct sequencing
of all coding regions at Myriad Genetics. Five deleterious
mutations were identified for these high-risk patients.
All five mutations detected at Myriad Genetics were then
analyzed for all cases; these were mutations found in
exons 11, 12, and 15 (IVS14) of BRCA1 and exon 22
of BRCA2. Furthermore, we tested all case subjects for
mutations in exons 2 and 20 of BRCA1, to detect ad-
ditional mutations (specifically, the 185delAG mutation,
which has previously been described in two patients of
Pakistani ethnicity with cancer)—exon 20 of BRCA1
covers another founder mutation (5382insC) in the Jew-
ish population (Bar-Sade et al. 1998; Risch et al. 2001).
Analysis of BRCA1 exons 2, 12, 15 (IVS14), and 20
and BRCA2 exon 22 was performed by denaturing gra-
dient gel electrophoresis (Fodde and Losekoot 1994).
PCR primers were fluorescently labeled, and the PCR
fragments were visualized by use of a phosphorimager.
In total, we screened BRCA1 exons 2, 11, 12, 15
(IVS14), and 20 and BRCA2 exons 10, 11, and 22 in
all case subjects. It has been estimated that this testing
detects 70%–80% of all germline mutations in the cod-
ing regions of these two genes (Peto et al. 1999).
Control subjects were tested for the five recurrent
mutations—located in exon 11 of BRCA2 and exons 11
and 15 (IVS14) of BRCA1—observed in case subjects.
Exons 2 and 20 of BRCA1 were also screened in control
subjects.
Statistical Analysis
The observed number of cancer cases in first-degree
relatives was determined by review of family pedigrees.
Kaplan-Meier survival analysis was used for the calcu-
lation of the cumulative incidence of cancer in first-degree
relatives of BRCA1- and BRCA2-mutation–positive case
subjects. First-degree female relatives were considered to
be at risk for cancer from birth until death (or until age
at date of interview of the proband). The log-rank test
was used to assess the statistical significance of differences
in survival curves. The relative risk (RR) of cancer among
first-degree relatives of carriers were estimated by use of
the Cox proportional hazards model. For nominal data,
a test was used, and, for comparison of continuous2x
variables, a t test was used. The significance level was set
at .05, two sided. Statistical analysis was performed using
SPSS (version 11) for Windows.
Details on parental consanguinity were available for
97.7% of case subjects. Parental consanguinity was clas-
sified into four main types: no consanguinity, first cous-
ins or closer (e.g., double-first-cousin marriages), second
cousins, and third or more-distant cousins. Logistic re-
gression was used to generate an estimate of the effect
that parental consanguinity has on breast cancer risk.
In this analysis, covariates included age, ethnic group,
and annual income. Ethnic group was determined by
three categories: Punjabi, Sindhi, or other. There were
three categories of annual income: low (up to 50,000
Rs [∼$900]), high (at least 300,000 Rs [∼$5,000]), and
598
Table 2
Characteristics of BRCA1-/BRCA2-Mutation Carriers from Pakistan
FAMILY HISTORYb
SUBJECT (MUTATION CARRIED;
LOCATION)a
AGE AT ONSET
(years) ETHNICITY BR !50 50 OV Other
BR [n p 341]:
BRCA1 mutation:
47 (IVS14-1GrA) 35.5 Pashtun 1 1 0 0 2
49 (IVS14-1GrA) 39.9 Punjabi 7 3 4 5 4
90 (2080insA; exon 11) 35.5 Pashtun 3 3 0 2 5
133 (2080insA; exon 11) 38.5 Pashtun 3 3 0 2 5
102 (1912TrG; exon 11 ) 45 Mohajir 0 0 0 0 2
121 (185delAG; exon 2) 47.9 Punjabi 0 0 0 0 1
113 (1616delAAAT; exon 11) 35.6 Mohajir 0 0 0 1 3
204 (4284delAG; exon 12) 39.4 Mohajir 3 3 0 0 5
287 (4284delAG; exon 12) 40.4 Mohajir 2 1 1 0 0
316 (4184del4; exon 11) 35.1 Sindhi 0 0 0 0 0
1128 (4184del4; exon 11) 30.4 Punjabi 1 1 0 0 0
1056 (4184del4; exon 11) 31.4, 32.3c Punjabi 0 0 0 0 0
1019 (1476delG; exon 11) 37 Punjabi 1 1 0 0 1
1071 (2041insA; exon 11) 21 Punjabi 0 0 0 3 1
1119 (3889delAG; exon 11) 38.5 Punjabi 1 1 0 0 0
BRCA2 mutation:
75 (5302insA; exon 11) 48.4 Punjabi 1 0 1 0 1
83 (9140delA; exon 22) 40.3 Mohajir 1d 0 1d 0 0
223 (3337CrT; exon 11) 39.2 Memon 1 0 1 0 1
158 (3337CrT; exon 11) 40 Memon 1 0 1 0 3
168 (3913delG; exon 11) 62.1 Sindhi 2 0 2 0 2
1069 (5950delCT; exon 11) 39.7 Punjabi 0 0 0 0 0
1155 (6696delTC; exon 11) 61.4 Punjabi 0 0 0 3 0
130 (2674delG; exon 11) 39.6 Gujrati/Mohajir 0 0 0 0 0
OV [n p 116]:
BRCA1 mutation:
3 (4184del4; exon 11) 36.5 Punjabi 0 0 0 0 0
5 (2388delG; exon 11) 43.3 Mohajir 0 0 0 0 0
12 (2080insA; exon 11) 45.5 Pashtun 9 8 1 4 5
15 (894delG; exon 11) 54 Mohajir 0 0 0 0 0
16 (IVS14-1GrA) 60.1 Punjabi 8 4 4 4 4
28 (3405CrT; exon 11) 54.6 Mohajir 1 1 0 0 1
1004 (1956delA; exon 11) 46 Punjabi 1 1 0 0 0
1043 (2041insA; exon 11) 36.8 Punjabi 1 1 0 2 1
1063 (185insA; exon 2) 40.4 Punjabi 0 0 0 0 0
1165 (3889delAG; exon 11) 74.2 Punjabi 0 0 0 0 0
286 (1770insT; exon 11) 70 Baloch 0 0 0 0 0
1079 (4627CrA [S1503X]; exon 15) 40.7 Punjabi 1 1 0 0 0
24 (1013delTG; exon 11) 48.4 Mohajir/Aga Khani 0 0 0 0 1
BRCA2 mutation:
8 (5057delTG; exon 11) 46.8 Parsi 2 0 2 0 1
305 (3179delA; exon 11) 50 Mohajir 0 0 0 0 0
(continued)
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Table 2 (continued)
AGE AT ONSET OF
(years) FAMILY HISTORYb
SUBJECT (MUTATION
CARRIED; LOCATION)a OV BR ETHNICITY BR !50 50 OV Other
BR and OV [n p 4]e
BRCA1mutation:
1112 (1127delA; exon 11) 45.9 43.8 Punjabi 1 0 1 0 0
1173 (2266delG; exon 11) 52.2 52.5 Punjabi 0 0 0 0 0
1183 (2722CrG; exon 11) 52.8 35 Kashmiri 1 1 0 0 0
BRCA2 mutation:
1168 (6679insAA; exon 11) 50 46.5 Punjabi 0 0 0 0 0
FAMILY HISTORYb
SUBJECT (MUTATION CARRIED;
LOCATION)a REFERRAL TYPE ETHNICITY BR !50 50 OV Other
Outside study [np 3]
BRCA1 mutation:
220 (2524delTG; exon 11) Woman at risk Sindhi 2 2 0 0 0
1185 (3717CrT; exon 11) OV (after study
closure)
Punjabi 1 0 1 0 1
BRCA2 mutation:
203 (5869delAAAT; exon 11) Male BR Sindhi 4 3 1 0 6
NOTE.— BR p breast cancer; OV p ovarian cancer.
a Four-digit study numbers denote case subjects from JHL; candidate founder mutations are underlined.
b !50 p No., in each family, of breast cancers diagnosed at age !50 years; 50 p no., in each family, of breast cancers diagnosed at age
50 years.
c Bilateral BR.
d Male BR.
e Ascertained as incident cases of OV.
middle (determined by the intervening range). Estimates
of odds ratios (ORs) were also generated for subgroups
of patients, by age at diagnosis, ethnic group, place of
residence, and income.
The published cancer rates from the Karachi Cancer
Registry were also used to compare cancer risk in carriers
of mutations in the BRCA1 and BRCA2 genes to risk in
the general population (Bhurgri et al. 2000). The expected
number of cases was calculated from the age-specific in-
cidence rates from the Karachi Cancer Registry. The RR
of cancer in first-degree relatives was estimated by com-
parison of the observed number of cases to the expected
figures. The CIs were calculated with the assumption of
a Poisson distribution (Breslow and Day 1987).
Results
The present study includes 341 case subjects with invasive
breast cancer, 120 case subjects with invasive epithelial
ovarian cancer, and 200 unaffected female control sub-
jects. The mean age at diagnosis of breast cancer was 41.3
years (range 21–81 years). The mean age at diagnosis of
ovarian cancer was 46.4 years (range 21–79 years).
Among the 341 women diagnosed with breast cancer, 23
(6.7%; 95% CI 4.1%–9.4%) mutations were identified,
of which 15 were inBRCA1 (4.4%; 95% CI 2.2%–6.6%)
and 8 were inBRCA2 (2.3%; 95% CI 0.7%–4.0%) (table
1). A greater proportion of women who had breast cancer
diagnosed at age !40 years were carriers (9.4%), com-
pared with those who had breast cancer diagnosed at age
40 years (4.4%) ( ). The mean ages at diag-Pp .083
noses of breast cancer in carriers and noncarriers were
40.1 years and 41.4 years, respectively ( ). ThePp .52
BRCA1-mutation–positive breast cancer case subjects
had cancer diagnosed, on average, 10 years earlier than
did the BRCA2-mutation–positive case subjects—at ages
36.8 and 46.4 years, respectively ( ).Pp .01
Among the 120 women diagnosed with ovarian cancer,
19 (15.8%; 95% CI 9.2%–22.4%) mutations were iden-
tified, of which 16 were in BRCA1 (13.3%; 95% CI
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7.2%–19.5%) and 3 were in BRCA2 (2.5%; 95% CI
1.0%–5.3%). Four women with ovarian carcinoma had
previously had invasive breast cancer diagnosed, and all
four were mutation positive; one BRCA2 mutation and
three BRCA1 mutations were identified. In contrast to
case subjects with breast cancer, a smaller proportion of
women who had ovarian cancer diagnosed at age !40
years were carriers, compared with those in whom di-
agnosis was made at age 40 years (6.1% vs. 19.5%,
respectively; ). The BRCA1-/BRCA2-muta-Pp .094
tion–positive case subjects with ovarian cancer were, on
average, older than the noncarrier cases. The mean ages
at diagnoses of ovarian cancer in carriers and noncarriers
were 49.9 and 45.8 years, respectively ( ). ThePp .19
BRCA1- and BRCA2-mutation–positive case subjects
with ovarian cancer had cancer diagnosed at similar ages,
50.1 and 48.9 years, respectively ( ). Of note,Pp .86
there were no BRCA1 or BRCA2 mutations identified
among the 15 women in whom diagnosis was made at
age !30 years.
In total, 42BRCA1 and BRCA2mutations were iden-
tified among 461 women diagnosed with either breast
or ovarian cancer; 31 (74%) mutations were in BRCA1,
and 11 (26%) were in BRCA2 (table 2). No BRCA1
or BRCA2 mutations were identified for the 200 control
women. We observed 21 distinct BRCA1 mutations and
10 distinct BRCA2 mutations; 12 of the 21 BRCA1
mutations (57%) and 8 of the 10 BRCA2 mutations
(80%) were unique to the Pakistani population (see the
Breast Cancer Information Core [BIC] Web site). The
other mutations have been described in other popula-
tions (table 3). One woman with breast cancer diag-
nosed at age 47 years carried the BRCA1 185delAG
mutation.
Five BRCA1 mutations (2080insA, 3889delAG,
4184del4, 4284delAG, and IVS14-1GrA) and one
BRCA2 mutation (3337CrT) were identified in mul-
tiple unrelated patients. The two case subjects with the
BRCA1 2041insA mutation (1043 and 1071) are re-
lated by second degree. The BRCA1 2080insA mutation
was found in two families, both of Pashtun (Pathan)
ethnicity. The two families with the BRCA2 3337CrT
mutation belong to the Memon ethnic group. The two
families with the BRCA1 4284delAG mutation belong
to the Mohajir ethnic group. The BRCA1 IVS14-1GrA
mutation was found in two families, one of Punjabi
background and the other of Pashtun ethnicity. Three
of the four patients with the BRCA1 4184del4 mutation
were of Punjabi descent, and the other, who resided in
Karachi, identified herself as Sindhi.
Ten percent of the women with breast or ovarian can-
cer and 3% of the control subjects reported having a
first-degree relative in whom a diagnosis of breast cancer
had been made. A family history of breast cancer in any
relative was considered as a significant risk factor for
breast cancer ( ; 95% CI 2.2–7.4;ORp 4.0 Pp 2#
) and for ovarian cancer ( ; 95% CI 1.8–610 ORp 3.6
7.4; ). More than one-half (56.2%) of thePp .00046
case subjects with a family history of ovarian cancer were
found to carry a mutation in either BRCA1 or BRCA2.
However, fewer than one-fourth (23.5%) of the case sub-
jects with a family history of breast cancer were carriers.
Of the 461 overall case subjects, 34 (7.4%) belonged to
families that had a history of both breast and ovarian
cancer. In the families with a history of both breast and
ovarian cancer, the probability of detecting a BRCA1 or
BRCA2 mutation rose significantly with the increase in
the number of family members with either breast cancer
or ovarian cancer (table 4). Of the 42 case subjects who
had cancer associated withBRCA1 orBRCA2, 16 (38%)
reported no family history of breast cancer in any relative.
The cumulative cancer risk was estimated in the first-
degree relatives of BRCA1-/BRCA2-mutation–positive
case subjects (because subjects 16 and 49 are mother
and daughter, this family was included only once for
the cumulative risk analysis). A total of 13,950 person-
years was accumulated for 368 first-degree relatives in
41 mutation-positive families. Female first-degree rel-
atives had a higher cumulative cancer incidence (46%;
to age 85 years) than did male relatives (25%; to age
85 years; ) (fig. 1A). Male patients accountedPp .0072
for one-half of all cancers reported in BRCA2 families
and for 22% of cancers in BRCA1-mutation–positive
families. In BRCA2-mutation–positive families, male
and female relatives had similar cumulative risks for
cancer of any site. Male patients in BRCA2-mutation-
positive families developed cancers of the breast, head,
and neck, and male patients in BRCA1-mutation–pos-
itive families developed bladder, pancreatic, and testic-
ular cancers, as well as two cases of leukemia. The cu-
mulative lifetime risk of cancer to age 85 years in
first-degree relatives of BRCA2-mutation–positive case
subjects slightly exceeded that for BRCA1-mutation–
positive case subjects (fig. 1B); however, there was a
much greater cancer risk before age 50 years in BRCA1-
mutation–positive relatives than in BRCA2-mutation
positive relatives ( ). In particular, we ob-Pp .0047
served a higher cumulative incidence of cancer among
female first-degree relatives of BRCA1-mutation–pos-
itive case subjects compared to relatives of BRCA2-
mutation–positive case subjects ( ; 95% CIRRp 4.1
1.2–14.0; )—the risk difference was pro-Pp .014
nounced at age !50 years ( ) (fig. 1C). In fe-Pp .0035
male relatives of BRCA1-mutation carriers, 10 of 11
(91%) breast cancers and two of four (50%) ovarian
cancers occurred at age !50 years. Among women, the
cumulative incidence of breast cancer among first-de-
gree relatives of BRCA1-mutation carriers was 22%,
and that of ovarian cancer was 15%. There were too
few cases of breast or ovarian cancer (only one case of
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Table 3
BRCA1 and BRCA2 Mutations Reported in Multiple Pakistani and Non-Pakistani Patients
Mutation
No. of Pakistani Patients
(Ethnic Population[s])
No. of BIC Entriesa (Other
Ethnic Population[s])
BRCA1:
4284delAG 2 (Mohajir) 5 (Dutch, German)
4184delTCAAb 4 (Punjabi [3], Pashtun [1]) 39 (British, French, European)
3889delAG 2 (Punjabi) 5 (Dutch)
2722CrG (S868X) 1 (Kashmiri) 3 (Dutch)
2388delG 1 (Mohajir) 4 (not specified)
2080insA 3 (Pashtun) 1 (not specified)
185insA 1 (Punjabi) 16 (Dutch, Belgian)
185delAGc 1 (Punjabi) 490 (Ashkenazi Jewish)
IVS14-1GrA 3 (Punjabi [2], Pashtun [1]) …
BRCA2:
3337CrT (Q1037X) 2 (Memon) … (Chinese)
5950delCT 1 (Punjabi) 13 (German)
6696delTC 1 (Punjabi) 2 (Italian)
a See the BIC Web site.
b Previously reported in Indo-Pakistani families (Neuhausen et al. 1996).
c Previously reported in Pakistani patients (Bar-Sade et al. 1998; Risch et al. 2001).
Table 4
Proportion, by Family History of Cancer, of BRCA1-/BRCA2-
Mutation–Positive Probands with Breast and Ovarian Cancer
Family Structurea
No. Positive for Mutation
in BRCA1or BRCA2/Total (%)
Breast cancer only:
1 case 6/261 (2.3)
2 cases 8/54 (14.8)
3 cases 3/16 (18.8)
Breast and ovarian cancer (breast):
1 case 9/25 (36.0)
2 cases 1/3 (33.3)
3 cases 5/6 (83.3)
Ovarian cancer only:
1 case 10/96 (10.9)
Breast and ovarian cancer (ovary):
1 case 7/22 (31.8)
2 cases 2/4 (50.0)
3 cases 6/8 (75.0)
a The cancer in the proband is included in the number given.
each) among relatives of BRCA2-mutation carriers to
construct reliable risk estimates. No cancers were re-
ported at age !50 years for relatives of probands who
were BRCA2-mutation carriers.
Age- and sex-specific cancer rates from the Karachi
Cancer Registry were used for comparison of cancer
incidence in the first-degree relatives of BRCA1- or
BRCA2-mutation carriers (table 5) (Bhurgri et al. 2000).
These estimates confirm that female BRCA1- orBRCA2-
mutation carriers from Pakistan have a greatly increased
risk of cancer at age !40 years.
Parental consanguinity of any type was reported
among 42.6% of all subjects, including 44.6% and 38%
of case and control subjects, respectively ( ). APp .12
higher proportion of case subjects with breast cancer
than of control subjects were the progeny of first-cousin
marriages ( ; 95% CI 1.4–3.3; ) (ta-ORp 2.1 Pp .001
ble 6). The effects were significant for early-onset breast
cancer (age !40 years) ( ; 95% CI 1.5–4.9;ORp 2.7
) and for ovarian cancer ( ; 95%Pp .0008 ORp 2.4
CI 1.4–4.2; ). More-distant consanguineousPp .0017
marriages were not significantly associated with cancer
status (data not shown).
Thirty-nine percent of case and control subjects were
of Punjabi ethnicity, and consanguinity is known to be
more common among individuals of this ethnic popu-
lation of Pakistan (Shami et al. 1989; Bittles et al. 1993;
Yaqoob et al. 1993). Forty percent of Punjabi case sub-
jects and 21.3% of Punjabi control subjects were the
progeny of a first-cousin marriage ( ). Table 7Pp .018
compares the proportions of case and control subjects
who reported parental consanguinity at the first-cousin
level, by age group, ethnicity, residence, and socioeco-
nomic status. Multivariate analysis was performed, to
assess the effect that potential confounders, such as age,
ethnic group, and socioeconomic status, have on the
observed association between consanguinity and can-
cer risk. The associations were not altered by the in-
clusion of the potentially confounding variables in this
population.
Discussion
In the major Pakistani cities of Karachi and Lahore,
breast cancer constitutes up to one-third of all malignant
tumors in female patients, and ovarian cancer is the most
common cancer of gynecologic origin (Malik et al. 1992;
Bhurgri et al. 2000). The newly established Karachi Can-
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Figure 1 Cumulative incidence of cancer at any site among male
(solid line) and female (hatched line) first-degree relatives of BRCA1-
and BRCA2-mutation carriers (A), among first-degree relatives of
BRCA1-mutation (solid line) and BRCA2-mutation (hatched line) car-
riers (B), and among first-degree relatives of BRCA1-mutation (solid
line) and BRCA2-mutation (hatched line) carriers (C).
cer Registry reported the highest ASR of breast cancer
and one of the highest ASRs of ovarian cancer recorded
for any Asian population, excluding Israel (Bhurgri et
al. 2000). Ours is the first report of the prevalence of
BRCA1 and BRCA2 mutations in a large series of Pak-
istani patients with cancer. These patients were drawn
from two large medical practices; unfortunately, infor-
mation was not available on the characteristics of the
patients with cancer who attended the hospital but were
not included in the study. The patients whom we studied
may not represent the greater Pakistani population well
in terms of age, ethnic group, and so forth. For example,
they were diagnosed at a mean age of 41 years (42.7
years for Karachi patients and 38.2 years for Lahore
patients); these ages are less than the average age at onset
of breast cancer in Pakistan, and only 5% of these pa-
tients had cancer diagnosed at age !60 years.
We identified a total of 42 BRCA1 and BRCA2 mu-
tations; under the assumption of 100% sensitivity, this
represents mutation prevalences, in Pakistan, of 6.7%
for unselected patients with breast cancer and of 15.8%
for unselected patients with ovarian cancer. However,
the sensitivity of our mutation assay was estimated to
be !80%; therefore, the true mutation-prevalence es-
timates are likely to be close to 8% for breast cancer
and 20% for ovarian cancer. If the sensitivity of the
assay were !80%, then the mutation prevalence would
be even higher. Although they are based on relatively
small numbers, these prevalence estimates are among
the highest reported to date (Liede and Narod, in press).
Mutations in the BRCA1 gene accounted for 84% of
all mutations detected among Pakistani patients with
ovarian cancer. The high prevalence of BRCA1 muta-
tions observed in Pakistani patients with ovarian cancer
supports the observation of Risch et al. (2001), who
found BRCA1 mutations in 14% of Indo-Pakistani pa-
tients with ovarian cancer who resided in Ontario, Can-
ada. Surprisingly, we did not find that the BRCA1-
mutation–positive breast cancers were diagnosed at a
significantly earlier age than that of the noncarriers
(40.1 and 41.4 years, respectively). This situation differs
from that of most Western countries and is likely a
reflection of the very young average of the Pakistani
patients in the series that we studied. Only 5% of the
patients in this series were age 160 years; in part, this
may be a feature of the selected population under study.
Five BRCA1 mutations (2080insA, 3889delAG,
4184del4, 4284delAG, and IVS14-1GrA) and one
BRCA2 mutation (3337CrT) were identified in mul-
tiple patients and suggest founder effects. Two ad-
ditional mutation-positive families, ascertained out-
side the case-control study, are presented in table 2.
The majority of mutations described here are unique
to Pakistan, but 10 of the 42 mutations have been
described in other populations, including four mu-
tations reported for the Dutch population (table 3).
The “Jewish” BRCA1 185delAG mutation has been
described for non-Ashkenazi groups across the Mid-
dle East—as well as in Greece, Turkey, and England
(Yorkshire)—and in two Indo-Pakistani families (Bar-
Liede et al.: Contribution of BRCA1 and BRCA2 Mutations in Pakistan 603
Table 5
Cancer Incidence among 368 First-Degree Relatives of 41
BRCA1-/BRCA2-Mutation Carriers from Pakistan
PATIENT GROUPS BASED
ON TYPE OF CANCER
AND AGE (IN YEARS)
INCIDENCE
RR (95% CI)Observed Expecteda
Any cancer:
Male and female patients:
!40 8 .83 9.7 (4.2–19.0)
40 21 11.6 1.8 (1.1–2.8)
Overall 29 12.4 2.3 (1.6–3.3)
Male patients:
!40 1 .43 2.3 (0.03–12.9)
40 7 5.2 1.3 (0.54–2.8)
Overall 8 5.7 1.4 (0.61–2.8)
Female patients:
!40 7 .40 17.6 (7.0–36.2)
40 14 6.4 2.2 (1.2–3.7)
Overall 21 6.8 3.1 (1.9–4.7)
Breast cancer:
Female patients:
!40 7 .11 64.6 (25.9–133.1)
40 5 2.3 2.2 (.70–5.1)
Overall 12 2.4 5.0 (2.6–8.7)
a Based on data from the Karachi Cancer Registry (Bhurgri et al. 2000).
Sade et al. 1998; Risch et al. 2001). This mutation
occurs in an AG repeat region of BRCA1; a high
mutation rate in this repeat region may explain the
different haplotypes that are associated with non-
Ashkenazi ethnic groups (Xu et al. 1997; Bar-Sade et
al. 1998). The 185delAG mutation was detected in
one of the patients with breast cancer who was from
Karachi and was of Punjabi descent. Previously, five
mutations in BRCA1 have been reported for Indo-
Pakistani families from the United Kingdom and
Canada—including 185delAG, 1701del7, 1768delA,
2885delA, and 4184del4 (Neuhausen et al. 1996;
Moslehi et al. 1998; Risch et al. 2001).
The BRCA1 4184del4 mutation has been reported for
families from Britain, France, and elsewhere in Europe,
including two Indo-Pakistani families residing in Britain.
Haplotype studies determined independent origins for the
4184del4 mutation for the European and Indo-Pakistani
families (Neuhausen et al. 1996). The BRCA1 4184del4
mutation was the most common mutation described
here—detected in four patients and accounting for 13%
of all the BRCA1 mutations in the present study. This
mutation was found in three subjects of Punjabi descent
and one subject of Sindhi descent. Three mutations—
BRCA1 3889delAG, BRCA1 4284delAG, and BRCA2
3337CrT—were specific to the Punjabi, Mohajir,
and Memon ethnic groups, respectively. The BRCA2
3337CrT mutation has previously been described in
three Chinese patients from Hong Kong, although hap-
lotype studies could not establish an ancestral link
(Khoo et al. 2000, 2002).
Historically, the region that encompasses Pakistan ex-
perienced successive waves of migrations from the north-
west, as well as internal migrations across the Indus valley
and the Indian subcontinent. In more recent times, the
region experienced massive migrations of refugees—from
India, after the partition of British India in 1947, and,
more recently, from Afghanistan. Pakistani society is
composed of many ethnic groups, and many of these are
common to the populations of India, Afghanistan, Ban-
gladesh, and Iran. The Pashtun, from the North-West
Frontier Province of Pakistan, are estimated at 11 million
in number. Approximately the same number of Pashtun
live in Afghanistan, where they are the major ethnic
group. Two BRCA1 mutations (2080insA and IVS14-
1GrA) were identified among Pashtun case subjects, al-
though only the BRCA1 2080insA mutation was found
exclusively in Pashtun women. Three BRCA1 mutations
(4184del4, 3889delAG, and IVS14-1GrA) were found
among women of Punjabi descent, and one BRCA1 mu-
tation (4284delAG) was found among women of Mo-
hajir descent.
Nearly one-half of all Pakistanis speak Punjabi. The
next most commonly spoken language is Sindhi (12%),
followed by the Punjabi variant Siraiki (10%), Pashtu
(8%), and Balochi (3%). Although Urdu is the official
national language, it is spoken as a native tongue by
the !10% of the population who identify themselves as
Mohajirs. The ethnic composition of Pakistan corre-
sponds to the linguistic distributions in the population,
at least among the largest groups. The subjects whom
we studied are representative of the general population
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Table 6
Results from Univariate and Multivariate Analyses of Parental Consanguinity
PARENTAL CONSANGUINITY RESULTS IF PARENTS ARE
First Cousins or Closer
Related OR (95% CI)
PATIENT GROUP
Not Related,
No. (%a) No. (%a)
OR (95% CI),
Crude No. (%a) Crude Adjustedb
Control subjects (n p 200)c 124 (62.0) 76 (38.0) … 31 (15.5) … …
Case subjects:
Subjects with breast cancer:
Age !40 years (n p 159)d 72 (48.0) 78 (52.0) 1.56 (.98–2.51) 49 (32.7) 2.72 (1.51–4.88) 2.55 (1.33–4.87)
Age 40 years (n p 182) 110 (61.5) 69 (38.5) 1.31 (.73–2.37) 43 (24.0) 1.64 (.79–3.4) 1.84 (.88–3.85)
Overall (n p 341) 182 (55.3) 147 (44.7) 1.32 (.92–1.89) 92 (28.0) 2.12 (1.35–3.33) 2.24 (1.37–3.66)
Subjects with ovarian cancer (n p 120) 65 (55.6) 52 (44.4) 1.3 (.82–2.07) 36 (30.8) 2.42 (1.4–4.19) 2.41 (1.24–4.67)
BRCA1-/BRCA2-mutation carriers
(n p 42) 23 (54.8) 19 (45.2) 1.35 (.69–2.64) 11 (26.2) 1.93 (.88–4.25) 2.04 (.75–5.55)
Noncarriers (n p 419) 224 (55.4) 180 (44.6) 1.31 (.93–1.85) 117 (29.0) 2.22 (1.43–3.45) 2.34 (1.44–3.78)
Overall (n p 461) 248 (55.5) 199 (44.5) 1.32 (.94–1.85) 128 (28.7) 2.19 (1.42–3.39) 2.27 (1.41–3.66)
a Percentages were calculated for subjects for whom this information was available.
b Adjusted for age, ethnic group, family history (first degree), and socioeconomic status.
c Reference group.
d Reference group categorized by age groups.
Table 7
Frequency of First-Cousin Marriages in Case and Control Subjects’
Parents, Stratified by Subgroup
SUBGROUP
NO. (%a) OF
PCase Subjects Control Subjects
Age (in years):
20–29 16 (42.1) 7 (11.3) 0
30–39 47 (30.5) 13 (18.6) .04
40–49 46 (26.0) 7 (15.9) .17
50–59 11 (18.0) 3 (20.0) 1
60 8 (26.7) 1 (11.1) .65
Ethnicity:
Punjabi 81 (38.6) 10 (21.3) .02
Sindhi 7 (25.0) 3 (18.8) .72
Other 40 (17.9) 18 (13.1) .24
Province of residence:
Punjab 63 (40.1) 8 (34.8) .65
Sindh 64 (21.6) 22 (12.8) .01
Other 1 (12.5) 1 (20.0) 1
Income:
Low 52 (39.7) 15 (15.6) 56.5# 10
Middle 56 (24.3) 11 (14.7) .08
High 13 (23.2) 5 (18.5) .78
a Percentages were calculated for subjects for whom this informa-
tion was available.
of Pakistan: 39% were Punjabi, 7% were Sindhi, 7%
were Pashtun, 4% were Memon, 3% were Gujrati, 3%
were Parsi (Zorastrian), and 6% were members of other
ethnic groups (Baloch, Kashmiri, etc.). Each ethnic
group is primarily concentrated in its home province,
with most Mohajirs residing in urban Sindh (Karachi).
Since the majority (90%) of control subjects and two-
thirds of case subjects were recruited from the Karachi
region, we have overrepresentation (31%) of subjects
who belong to the Mohajir ethnic group.
Consanguineous marriage is practiced in much of the
Muslim world—including North and sub-Saharan Af-
rica, the Middle East, the West, and South Asia—and
by migrants from these regions. Approximately 40% of
the Pakistani population have practiced consanguinity
for ∼300 years—typically, inbreeding occurs within
thousands of village isolates (Consanguinity and health
1991). Two large studies that have examined adult can-
cer risk and consanguinity have reported conflicting re-
sults. In the first of these studies, Shami et al. (1991)
examined consanguinity among 825 outpatients in Is-
lamabad, Pakistan. Parental consanguinity was associ-
ated with deafness, mutism, mental retardation, and
cancer in adults, and, of the 20 patients with breast
cancer, 15 were the progeny of a first-cousin marriage
(Shami et al. 1991). Recently, in another study, Denic
and Bener (2001) examined consanguinity among 1,445
women who attended primary health care clinics in the
United Arab Emirates. A protective effect on breast can-
cer risk was reported for consanguinity ( ;RRp 0.66
); however, the effect was statistically significantPp .08
only for women aged 40–50 years ( ;RRp 0.50 Pp
) (Denic and Bener 2001). In the present study,.02
daughters of parents who were first cousins were at
approximately twice the risk of breast and ovarian can-
cer than were daughters of unrelated parents. Although
the control women whom we studied were generally
younger, of lower socioeconomic status, and less likely
to identify themselves as Punjabi, these factors did not
appear to underlie the observed associations for paren-
tal consanguinity. We estimate that 20% of cases of
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breast cancer diagnosed in women aged !40 years are
attributable to first-cousin marriages.
The major (nongenetic) risk factors for breast and
ovarian cancer are reproductive and dietary factors.
Pakistani women have a low frequency of these tradi-
tional risk factors. The female population, on average,
has high levels of fertility, early age at first pregnancy,
multiple births, and prolonged breast-feeding. Although
the age at first marriage has been gradually rising,
women in consanguineous unions marry at earlier ages
and are less likely to use modern contraceptive methods
than are women from nonconsanguineous marriages
(Hussain and Bittles 1999). Generally, Pakistani women
do not use exogenous hormones (oral contraception or
estrogen-replacement therapy). They generally do not
smoke tobacco products, although some women prac-
tice chewing pan and pan tobacco. Furthermore, the
population of Pakistan is predominantly Muslim (97%),
and alcohol consumption is uncommon.
We conclude that genetic factors play a significant
role in breast and ovarian cancer incidence in Pakistan.
The prevalence and penetrance estimates for Pakistan
suggest that dominant BRCA1 and BRCA2 mutations
are significant contributors to breast and ovarian cancer
incidence in this population. The association between
parental consanguinity and breast cancer risk suggests
that recessive genes may play a role in the etiology of
breast cancer in young women. Our data are also per-
tinent to immigrant women from Pakistan who may
seek genetic counseling, for cancer risk, in North Amer-
ica and Europe—as well as to women from the same
ethnic groups in countries such as India, Afghanistan,
Bangladesh, and Iran.
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